CoChat

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Open access

The DOI matches its Crossref record; 59 of the 62 references it cites were found in a registry or an index.

Abstract

Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with localized urothelial carcinoma 1,2, with one study reporting data in cisplatin-ineligible patients who received anti-PD-L1 monotherapy 2. The study reported that patients with bulky tumors, a known high-risk feature defined as greater than clinical T2 disease, had fewer responses, with pathological complete response rate of 17%2. Here we report on the first pilot combination neoadjuvant trial ( NCT02812420 ) with anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab) in cisplatin-ineligible patients, with all tumors identified as having high-risk features (n = 28). High-risk features were defined by bulky tumors, variant histology, lymphovascular invasion, hydronephrosis and/or high-grade upper tract disease 3-5. The primary endpoint was safety and we observed 6 of 28 patients (21%) with grade ≥3 immune-related adverse events, consisting of asymptomatic laboratory abnormalities (n = 4), hepatitis and colitis (n = 2). We also observed pathological complete response of 37.5% and downstaging to pT1 or less in 58% of patients who completed surgery (n = 24). In summary, we provide initial safety, efficacy and biomarker data with neoadjuvant combination anti-PD-L1 plus anti-CTLA-4, which warrants further development for patients with localized urothelial carcinoma, especially cisplatin-ineligible patients with high-risk features who do not currently have an established standard-of-care neoadjuvant treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-020-1086-y

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Research works printed but not linked: 1

  1. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Bladder Cancer, Vol. 2019 (NCCN, 2019).

Cited by

See all 349

Metadata

Authors
Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., Shah, A. Y., Msaouel, P., Corn, P., Wang, J., Papadopoulos, J. N., Yadav, S. S., Blando, J. M., Duan, F., Basu, S., Liu, W., Shen, Y., Zhang, Y., Macaluso, M. D., Wang, Y., Chen, J., Zhang, J., Futreal, A., Dinney, C., Allison, J. P., Goswami, S., & Sharma, P.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Gao, Jianjun
  • Sharma, Padmanee
Venue
Nature Medicine
Published
2020-10-12
Volume
26
Issue
12
Pages
1845-1851
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3092302767
Cited by
318
References
62
Citations by year
2026: 26 · 2025: 47 · 2024: 56 · 2023: 61 · 2022: 72 · 2021: 47 · 2020: 9
FWCI
44.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA016672)
Topics
  • Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
Keywords
urothelial carcinoma, bladder cancer, neoadjuvant immunotherapy, PD-L1 blockade, CTLA-4 blockade, durvalumab, tremelimumab, cisplatin-ineligible patients, high-risk features, pathological complete response, tumor downstaging, immune-related adverse events, predictive biomarkers, immune checkpoint inhibitors
MeSH terms
Antineoplastic Agents, Immunological, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Cisplatin, Female, Humans, Male, Middle Aged, Neoplasm Staging, Risk Factors, Urothelium, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. https://app.cochat.ai/papers/10.1038/s41591-020-1086-y
The paper
Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., Shah, A. Y., Msaouel, P., Corn, P., Wang, J., Papadopoulos, J. N., Yadav, S. S., Blando, J. M., Duan, F., Basu, S., . . . Sharma, P. (2020). Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-020-1086-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.